Literature DB >> 8726467

Correction or transfer of immunodeficiency due to TNF-LT alpha deletion by bone marrow transplantation.

M Müller1, H P Eugster, M Le Hir, A Shakhov, F Di Padova, C Maurer, V F Quesniaux, B Ryffel.   

Abstract

BACKGROUND: Mice with inactivated tumor necrosis factor (TNF) and lymphotoxin alpha (LT alpha) genes have profound abnormalities of the immune system including lymphocytosis, lack of lymph nodes, undifferentiated spleen, hypoimmunoglobulinaemia, and defective Ig class switch. Here, we asked whether this phenotype is due to incompetent lymphohemopoietic progenitors or to a defective environment.
MATERIALS AND METHODS: Lethally irradiated TNF-LT alpha-deficient and wild-type mice received bone marrow cells from either TNF-LT alpha-deficient or wild-type mice. The reconstitution and transfer of the phenotype was followed by morphological and functional analyses.
RESULTS: Bone marrow cells from wild-type mice restored the synthesis of TNF and LT alpha, corrected the splenic microarchitecture, normalized the lymphocyte counts in the circulation, and repopulated the lamina propria with IgA-producing plasma cells of TNF-LT alpha-deficient mice. Furthermore, the formation of germinal centers in the spleen and the defective Ig class switch in response to a T-cell dependent antigen was corrected, while no lymph nodes were formed. Conversely, the TNF-LT alpha phenotype could be transferred to wild-type mice by bone marrow transplantation after lethal irradiation.
CONCLUSIONS: These data demonstrate that most TNF- and LT alpha-producing cells are bone marrow derived and radiosensitive, and that the immunodeficiency due to TNF-LT alpha deletion can be corrected to a large extent by normal bone marrow cell transplantation. The genotype of the donor bone marrow cells determines the functional and structural phenotype of the TNF-LT alpha-deficient adult murine host, with the exception of lymph node formation. These findings may have therapeutic implications for the restoration of genetically defined immunodeficiencies in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726467      PMCID: PMC2230110     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  28 in total

Review 1.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

2.  Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma.

Authors:  M J Androlewicz; J L Browning; C F Ware
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

3.  Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid.

Authors:  M Baens; M Chaffanet; J J Cassiman; H van den Berghe; P Marynen
Journal:  Genomics       Date:  1993-04       Impact factor: 5.736

4.  Molecular cloning and expression of a receptor for human tumor necrosis factor.

Authors:  T J Schall; M Lewis; K J Koller; A Lee; G C Rice; G H Wong; T Gatanaga; G A Granger; R Lentz; H Raab
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

5.  Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor.

Authors:  H Loetscher; Y C Pan; H W Lahm; R Gentz; M Brockhaus; H Tabuchi; W Lesslauer
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

6.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

7.  Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes.

Authors:  J Rothe; W Lesslauer; H Lötscher; Y Lang; P Koebel; F Köntgen; A Althage; R Zinkernagel; M Steinmetz; H Bluethmann
Journal:  Nature       Date:  1993-08-26       Impact factor: 49.962

8.  Tumor necrosis factor-alpha gene expression in the tissues of normal mice.

Authors:  J S Hunt; H L Chen; X L Hu; T Y Chen; D C Morrison
Journal:  Cytokine       Date:  1992-09       Impact factor: 3.861

9.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

Authors:  K Pfeffer; T Matsuyama; T M Kündig; A Wakeham; K Kishihara; A Shahinian; K Wiegmann; P S Ohashi; M Krönke; T W Mak
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

10.  The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation.

Authors:  G Aversa; J Punnonen; J E de Vries
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Lymphotoxins: from cytotoxicity to lymphoid organogenesis.

Authors:  H von Boehmer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88.

Authors:  Cecile M Fremond; Vladimir Yeremeev; Delphine M Nicolle; Muazzam Jacobs; Valerie F Quesniaux; Bernhard Ryffel
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

3.  Membrane tumor necrosis factor confers partial protection to Listeria infection.

Authors:  David Torres; Laure Janot; Valerie F J Quesniaux; Sergei I Grivennikov; Isabelle Maillet; Jonathon D Sedgwick; Bernhard Ryffel; Francois Erard
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

4.  Long-term control of Mycobacterium bovis BCG infection in the absence of Toll-like receptors (TLRs): investigation of TLR2-, TLR6-, or TLR2-TLR4-deficient mice.

Authors:  Delphine Nicolle; Cécile Fremond; Xavier Pichon; André Bouchot; Isabelle Maillet; Bernhard Ryffel; Valerie J F Quesniaux
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

5.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Murine cerebral malaria development is independent of toll-like receptor signaling.

Authors:  Dieudonnée Togbe; Louis Schofield; Georges E Grau; Bruno Schnyder; Victorine Boissay; Sabine Charron; Stéphanie Rose; Bruce Beutler; Valérie F J Quesniaux; Bernhard Ryffel
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 7.  Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury.

Authors:  Dieudonnée Togbe; Silvia Schnyder-Candrian; Bruno Schnyder; Emilie Doz; Nicolas Noulin; Laure Janot; Thomas Secher; Pamela Gasse; Carla Lima; Fernando Rodrigues Coelho; Virginie Vasseur; François Erard; Bernhard Ryffel; Isabelle Couillin; Rene Moser
Journal:  Int J Exp Pathol       Date:  2007-12       Impact factor: 1.925

8.  Toll-like receptor 2 is required for optimal control of Listeria monocytogenes infection.

Authors:  David Torres; Mathieu Barrier; Franck Bihl; Valerie J F Quesniaux; Isabelle Maillet; Shizuo Akira; Bernhard Ryffel; François Erard
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

9.  Membrane TNF confers protection to acute mycobacterial infection.

Authors:  Cecile Fremond; Nasiema Allie; Ivy Dambuza; Sergei I Grivennikov; Vladimir Yeremeev; Valerie F J Quesniaux; Muazzam Jacobs; Bernhard Ryffel
Journal:  Respir Res       Date:  2005-11-14

10.  Protective role of membrane tumour necrosis factor in the host's resistance to mycobacterial infection.

Authors:  Nasiema Allie; Lena Alexopoulou; Valerie J F Quesniaux; Lizette Fick; Ksanthi Kranidioti; George Kollias; Bernhard Ryffel; Muazzam Jacobs
Journal:  Immunology       Date:  2008-06-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.